Ally Bridge Group’s Soleno Therapeutics SLNO Stock Holding History

Ally Bridge Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200,000	Closed	-$6.7M	–	36
2026 Q1	$6.7M	Buy	200,000 +31,971	+19%	+$1.25M	5.41%	3
2025 Q4	$7.78M	Sell	168,029 -134,454	-44%	-$7.37M	8.1%	3
2025 Q3	$20.4M	Buy	302,483 +123,664	+69%	+$9.17M	12.45%	1
2025 Q2	$15M	Buy	178,819 +58,370	+48%	+$4.37M	12.47%	2
2025 Q1	$8.61M	Buy	120,449 +32,820	+37%	+$1.6M	7.76%	3
2024 Q4	$3.94M	Buy	+87,629	New	+$4.54M	3.38%	11
2024 Q3	–	Sell	-286,162	Closed	-$11.7M	–	34
2024 Q2	$11.7M	Sell	286,162 -50,324	-15%	-$2.13M	6.96%	1
2024 Q1	$14.4M	Buy	336,486 +26,536	+9%	+$1.2M	8.01%	2
2023 Q4	$12.5M	Buy	+309,950	New	+$8.82M	7.43%	3

Ally Bridge Group's SLNO Position: Q2 2026 in Review

Ally Bridge Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 200,000 shares — an estimated $6.7M sold.

Ally Bridge Group first reported a position in SLNO in Q4 2023 and held it in 9 quarters. The position peaked at $20.4M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Ally Bridge Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Ally Bridge Group sold 200,000 Soleno Therapeutics shares in Q2 2026, an estimated $6.7M.
Ally Bridge Group first reported a position in Soleno Therapeutics in Q4 2023 and held it in 9 quarters.
Ally Bridge Group's Soleno Therapeutics position peaked at $20.4M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.